Kestra Medical Technologies (KMTS) financial statements
Kestra Medical Technologies reported revenue of $95M in fiscal 2026, up 84.9% a year over 2 years.
Net income was -$132M and the operating margin -141.6%, against -305.8% in 2024.
Free cash flow was -$117M.
The diluted share count rose 172% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Kestra Medical Technologies's 10-K filings with the SEC.
| Fiscal year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | $28M | $60M | $95M |
| Cost of revenue | $27M | $36M | $46M |
| Gross profit | $362,000 | $24M | $49M |
| Research and development | $15M | $16M | $19M |
| Selling, general and admin | $70M | $115M | $164M |
| Operating income | -$85M | -$106M | -$135M |
| Interest expense | $6M | $8M | $8M |
| Pre-tax income | -$94M | -$114M | -$131M |
| Income tax | $24,000 | $135,000 | $294,000 |
| Net income | -$94M | -$114M | -$132M |
| EPS (diluted) | -$5.07 | -$5.13 | -$2.43 |
| Diluted shares | 20M | 25M | 54M |
| Gross margin | 1.3% | 40.5% | 51.4% |
| Operating margin | -305.8% | -177.8% | -141.6% |
| Net margin | -338.4% | -190.3% | -138.4% |
Balance sheet
Fiscal years, from Kestra Medical Technologies's 10-K filings with the SEC.
| Fiscal year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Cash and short-term investments | $8M | $238M | $262M |
| Receivables | $2M | $8M | $15M |
| Total current assets | $15M | $255M | $222M |
| Property, plant and equipment | $26M | $35M | $59M |
| Total assets | $46M | $296M | $358M |
| Total current liabilities | $33M | $38M | $50M |
| Long-term debt | $43M | $41M | $43M |
| Total liabilities | $78M | $90M | $99M |
| Shareholders' equity | -$209M | $205M | $260M |
| Net debt | $34M | -$196M | -$57M |
Cash flow
Fiscal years, from Kestra Medical Technologies's 10-K filings with the SEC.
| Fiscal year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Operating cash flow | -$72M | -$78M | -$82M |
| Capital spending | $12M | $23M | $35M |
| Free cash flow | -$84M | -$101M | -$117M |
| Stock-based compensation | $1M | $24M | $34M |
| Net borrowing | $6M | — | — |
| Free cash flow margin | -303.7% | -168.1% | -122.6% |
Questions
What was Kestra Medical Technologies's revenue in 2026?
$95M in fiscal 2026, from its 10-K filing.
How much free cash flow does Kestra Medical Technologies generate?
-$117M in fiscal 2026 (operating cash flow minus capital spending).
From Kestra Medical Technologies's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.